Difficulty: Medium
Average Score: 67%
Practice
Pilocarpine reduces intraocular tension in open-angle glaucoma by
Correct answer
B
Rationale
In open-angle glaucoma, the main pathophysiological mechanism is an increase in intraocular pressure (IOP) due to impaired drainage of aqueous humor. Pilocarpine, a parasympathomimetic drug, is used to reduce IOP by constricting the ciliary muscle in the eye. This constriction results in the opening of the trabecular meshwork, facilitating the outflow of aqueous humor and thus reducing IOP.
Option A, contracting sphincter pupillae, is not correct because while pilocarpine does indeed cause miosis (pupillary constriction), this action is separate from its mechanism of action in reducing IOP in glaucoma.
Option C, reducing aqueous formation, is not correct because pilocarpine does not actually decrease the production of aqueous humor. Instead, it works by increasing the outflow of existing aqueous humor.
Option D, enhancing uveoscleral outflow, is not correct because pilocarpine primarily affects the conventional outflow pathway through the trabecular meshwork rather than the uveoscleral outflow pathway.
Understanding the pharmacological actions of pilocarpine in reducing IOP is crucial for healthcare professionals managing patients with glaucoma. By knowing how pilocarpine works, clinicians can make informed decisions about its appropriate use and understand its potential side effects and contraindications. This knowledge is essential for optimizing patient care and outcomes in individuals with glaucoma.
Option A, contracting sphincter pupillae, is not correct because while pilocarpine does indeed cause miosis (pupillary constriction), this action is separate from its mechanism of action in reducing IOP in glaucoma.
Option C, reducing aqueous formation, is not correct because pilocarpine does not actually decrease the production of aqueous humor. Instead, it works by increasing the outflow of existing aqueous humor.
Option D, enhancing uveoscleral outflow, is not correct because pilocarpine primarily affects the conventional outflow pathway through the trabecular meshwork rather than the uveoscleral outflow pathway.
Understanding the pharmacological actions of pilocarpine in reducing IOP is crucial for healthcare professionals managing patients with glaucoma. By knowing how pilocarpine works, clinicians can make informed decisions about its appropriate use and understand its potential side effects and contraindications. This knowledge is essential for optimizing patient care and outcomes in individuals with glaucoma.